The Top 5 Analyst Questions From Zimmer Biomet's Q4 Earnings Call

Zimmer Biomet’s fourth quarter results were greeted positively by the market, with management crediting strong execution in the U.S. and robust demand for recently launched products as key drivers. CEO Ivan Tornos highlighted the impact of new product adoption, especially in knee and hip implants, and the effectiveness of direct-to-patient marketing campaigns. Tornos pointed to continued gains in robotics and navigation technologies, as well as double-digit growth in the company’s cranio-maxillofacial and upper extremities segments. The quarter also benefited from capital equipment sales and higher procedure volumes, with Tornos emphasizing, “the lion’s share of the performance is better execution,” especially on recent product launches.

Is now the time to buy ZBH? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Zimmer Biomet’s Q4 Earnings Call

• Matthew Blackman (TD Cowen) asked about the rationale and timeline for the U.S. salesforce transition; CEO Ivan Tornos detailed the shift to a specialized, fully dedicated team, explaining the decision was driven by benchmarking against competitors and new product readiness, with completion expected by end of 2027.
• Rick Wise (Stifel) questioned why guidance was more cautious despite recent growth; Tornos cited the disruptive nature of the salesforce overhaul and the need to ensure durable, sustainable growth as reasons for the tempered outlook.
• Patrick Wood (Morgan Stanley) inquired about the outlook for pricing and mix; CFO Suketu Upadhyay explained that regulatory price resets in Japan and China, along with ongoing U.S. competition, contribute to expected pricing erosion in 2026.
• Vijay Kumar (Evercore ISI) asked for specifics on the impact and pacing of the salesforce reorganization; Tornos and Upadhyay noted that disruption would be front-loaded, with productivity gains expected as the transition progresses.
• Ryan Zimmerman (BTIG) focused on Paragon 28’s contribution; Tornos acknowledged slightly lower-than-expected revenue accretion but reaffirmed double-digit growth targets for the acquired business and highlighted upcoming product launches.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will closely monitor (1) the pace and impact of the U.S. salesforce transformation, especially in accelerating new product adoption; (2) progress on gross and operating margin stabilization as cost and pricing pressures persist; and (3) the integration and performance of recent acquisitions like Paragon 28 and Monogram. Execution on major product launches, such as the MBOS robotic system and iodine-coated implants, will also be key indicators of strategic progress.

Zimmer Biomet currently trades at $96.45, up from $89.73 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.